Gapping up
In reaction to strong earnings/guidance: EVDY +25.5%, FOR +18.9%, GWRE +10.8%, ANF +9%, NPTN +8.7%, CHUY +6.7%, DAR +6.7%, BV +3.2%, ROST +1.8%, BOBE +1.4%, (light volume), AVGR +0.5%, (also received 510(k) clearance from the FDA for an enhanced version of its Pantheris lumivascular atherectomy system)
M&A news: CKP +27% (to be acquired by CCL Industries for $10.15/share in cash, or ~$443 mln), JMI +18% (to be acquired by ARMOUR Residential REIT (ARR) for ~$7.14 per share)
Select EU financial related names showing strength: SAN +2.9%, PUK +2.4%, RIO +2.4%, DB +2.1%, BBVA +1.8%, ING +1.7%
Other news: EYEG +12.6% (receives an additional development milestone from Valeant (VRX) for the development and commercialization of the Company's EGP-437 combination product in the field of uveitis), REXX +12.1% (announces a new $175 mln joint exploration & development agreement in the Moraine East & Warrior North Operated Areas ), PRKR +10.1% (light volume; Parkervision files a petition with the Supreme Court requesting a review of the decision of the US Court of Appeals for the Federal Circuit in ParkerVision v. Qualcomm ), OCN +8.1% (cont vol pre-mkt), ZNGA +7.4% (appoints Frank Gibeau as CEO effective March 7; Co-founder & current CEO Mark Pincus will serve as Executive Chairman ), CVO +6.8% (light volume; announces five-year engagement with National Register Publishing), AWK +4.9% (American Water Works to replace CONSOL Energy in the S&P 500), CSX +3.1% (reports that CSX rejected a takeover approach from Canadian Pacific in January), CRC +2.3% (following 50%+ move higher), JD +1.7% (cont momentum, Shanghai +4% overnight), BABA +1.7% (cont momentum, Shanghai +4% overnight), BMRN +1.6% (granted orphan drug designation by the FDA for BMN 270 for the treatment of patients with hemophilia A), MOMO +1.2% (Shanghai +4% overnight)
Analyst comments: HABT +3.1% (upgraded to Outperform from Market Perform at Cowen), MELI +0.9% (upgraded to Hold from Reduce at HSBC Securities), AMZN +0.8% (initiated with an Outperform at BMO)
In reaction to strong earnings/guidance: EVDY +25.5%, FOR +18.9%, GWRE +10.8%, ANF +9%, NPTN +8.7%, CHUY +6.7%, DAR +6.7%, BV +3.2%, ROST +1.8%, BOBE +1.4%, (light volume), AVGR +0.5%, (also received 510(k) clearance from the FDA for an enhanced version of its Pantheris lumivascular atherectomy system)
M&A news: CKP +27% (to be acquired by CCL Industries for $10.15/share in cash, or ~$443 mln), JMI +18% (to be acquired by ARMOUR Residential REIT (ARR) for ~$7.14 per share)
Select EU financial related names showing strength: SAN +2.9%, PUK +2.4%, RIO +2.4%, DB +2.1%, BBVA +1.8%, ING +1.7%
Other news: EYEG +12.6% (receives an additional development milestone from Valeant (VRX) for the development and commercialization of the Company's EGP-437 combination product in the field of uveitis), REXX +12.1% (announces a new $175 mln joint exploration & development agreement in the Moraine East & Warrior North Operated Areas ), PRKR +10.1% (light volume; Parkervision files a petition with the Supreme Court requesting a review of the decision of the US Court of Appeals for the Federal Circuit in ParkerVision v. Qualcomm ), OCN +8.1% (cont vol pre-mkt), ZNGA +7.4% (appoints Frank Gibeau as CEO effective March 7; Co-founder & current CEO Mark Pincus will serve as Executive Chairman ), CVO +6.8% (light volume; announces five-year engagement with National Register Publishing), AWK +4.9% (American Water Works to replace CONSOL Energy in the S&P 500), CSX +3.1% (reports that CSX rejected a takeover approach from Canadian Pacific in January), CRC +2.3% (following 50%+ move higher), JD +1.7% (cont momentum, Shanghai +4% overnight), BABA +1.7% (cont momentum, Shanghai +4% overnight), BMRN +1.6% (granted orphan drug designation by the FDA for BMN 270 for the treatment of patients with hemophilia A), MOMO +1.2% (Shanghai +4% overnight)
Analyst comments: HABT +3.1% (upgraded to Outperform from Market Perform at Cowen), MELI +0.9% (upgraded to Hold from Reduce at HSBC Securities), AMZN +0.8% (initiated with an Outperform at BMO)